Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News BioSig Technologies Inc BSGM

Healthcare Medical Devices

BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is... see more

Add To Watchlist

Recent & Breaking News (NDAQ:BSGM)

ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19

GlobeNewswire July 8, 2020

BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors

GlobeNewswire July 1, 2020

BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering

GlobeNewswire June 29, 2020

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

GlobeNewswire June 24, 2020

ViralClear Partners with Catalent on Potential Treatment for COVID-19

GlobeNewswire June 22, 2020

ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19

GlobeNewswire June 17, 2020

Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19

GlobeNewswire June 8, 2020

ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19

GlobeNewswire June 5, 2020

BioSig Technologies's PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions

GlobeNewswire June 4, 2020

BioSig Technologies Expands Intellectual Property Portfolio

GlobeNewswire June 3, 2020

ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19

GlobeNewswire June 1, 2020

Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

GlobeNewswire May 28, 2020

ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib

GlobeNewswire May 20, 2020

FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear's Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed

GlobeNewswire May 18, 2020

ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19

GlobeNewswire May 14, 2020

Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.

GlobeNewswire May 7, 2020

Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

GlobeNewswire May 5, 2020

BioSig Resumes Clinical Activities with PURE EP System

GlobeNewswire May 1, 2020

ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal

GlobeNewswire April 30, 2020

BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19

GlobeNewswire April 24, 2020